Kenji Okonogi

2.3k citations

54 papers · 1.9k indexed · 1 hit paper · h-index 23

Co-authors: Yuji Iizawa Masanori Baba Mika Okamoto Naoyuki Kanzaki Mitsuru Shiraishi Kanji Meguro Osamu Nishimura Yasuaki Ogawa
Topics: Antibiotic Resistance in Bacteria (18 papers)Antibiotics Pharmacokinetics and Efficacy (16 papers)Antimicrobial Resistance in Staphylococcus (14 papers)
Cited by: Virology Molecular Medicine Infectious Diseases
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry FEBS Letters
Partner nations: Japan United States Brazil

In The Last Decade

Kenji Okonogi

54 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

1999 634 citations Masanori Baba, Mika Okamoto et al. profile →

Peers

Countries citing papers authored by Kenji Okonogi

Since Specialization

Citations

This map shows the geographic impact of Kenji Okonogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Okonogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Okonogi more than expected).

Fields of papers citing papers by Kenji Okonogi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Okonogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Okonogi. The network helps show where Kenji Okonogi may publish in the future.

Co-authorship network of co-authors of Kenji Okonogi

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Okonogi. A scholar is included among the top collaborators of Kenji Okonogi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Okonogi. Kenji Okonogi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599 2004 ·Journal of Infection and Chemotherapy ·Yuji Iizawa,Junko Nagai,Tomoyasu Ishikawa,Shohei Hashiguchi,Masafumi Nαkαo,Akio Miyake,Kenji Okonogi	68
2	Efficacy of TAK-457, a Novel Intravenous Triazole, against Invasive Pulmonary Aspergillosis in Neutropenic Mice 2002 ·Antimicrobial Agents and Chemotherapy ·(unknown),Naomi Kitamoto,Yuji Iizawa,Takashi Ichikawa,Katsumi Itoh,Tomoyuki Kitazaki,Kenji Okonogi	9
3	Studies on Anti-MRSA Parenteral Cephalosporins. III. Synthesis and Antibacterial Activity of 7.BETA.-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-[(E)-2-(1-alkylimidazo[1,2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylates and Related Compounds. 2001 ·The Journal of Antibiotics ·Tomoyasu Ishikawa,Keiji Kamiyama,Yutaka Nakayama,Yuji Iizawa,Kenji Okonogi,Akio Miyake	8
4	Studies on Anti-MRSA Parenteral Cephalosporins. IV. A Novel Water-soluble N-Phosphono Type Prodrug for Parenteral Administration. 2001 ·The Journal of Antibiotics ·Tomoyasu Ishikawa,Yutaka Nakayama,(unknown),Shin‐Ichi Niwa,Keiji Kamiyama,Shohei Hashiguchi,Yuji Iizawa,Kenji Okonogi,Akio Miyake	11
5	Studies on Anti-MRSA Parenteral Cephalosporins. I. Synthesis and Antibacterial Activity of 7.BETA.-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyiminoacetamido]-3-(substituted imidazo [1,2-b]-pyridazinium-1-yl)methyl-3-cephem-4-carboxylates and Related Compounds. 2000 ·The Journal of Antibiotics ·Tomoyasu Ishikawa,(unknown),Kenji Okonogi,Akio Miyake	27
6	Establishment of a CCR5-Expressing T-Lymphoblastoid Cell Line Highly Susceptible to R5 HIV Type 1 2000 ·AIDS Research and Human Retroviruses ·Masanori Baba,Hiroshi Miyake,Mika Okamoto,Yuji Iizawa,Kenji Okonogi	35
7	Optically Active Antifungal Azoles. VIII. Synthesis and Antifungal Activity of 1-((1R,2R)-2-(2,4-Difluoro- and 2-Fluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-3-(4-substituted phenyl)-2(1H,3H)-imidazolones and 2-Imidazolidinones. 1999 ·Chemical and Pharmaceutical Bulletin ·Tomoyuki Kitazaki,Akihiro Tasaka,Norikazu Tamura,Yoshihiro Matsushita,(unknown),(unknown),Kenji Okonogi,Katsumi Itoh	1
8	Therapeutic Efficacy of Cefozopran in a Murine Model of Haematogenous Pneumococcal Meningitis 1998 ·Chemotherapy ·Yuji Iizawa,(unknown),Masao Nakao,Kenji Okonogi	3
9	Optically Active Antifungal Azoles. VII. Synthesis and Antifungal Activity of Stereoisomers of 2-((1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-4-(4-(2,2,3,3-tetrafluoropropoxy)phenyl)-3(2H,4H)-1,2,4-triazolone (TAK-187). 1997 ·Chemical and Pharmaceutical Bulletin ·Akihiro Tasaka,Tomoyuki Kitazaki,Noboru Tsuchimori,Yoshihiro Matsushita,Rina Hayashi,Kenji Okonogi,Katsumi Itoh	16
10	Therapeutic effects of cefozopran against experimental mixed urinary tract infection with Enterococcus faecalis and Pseudomonas aeruginosa in mice 1997 ·Journal of Antimicrobial Chemotherapy ·Noboru Tsuchimori,Toshiyuki Yamazaki,Kenji Okonogi	3
11	Penicillin-binding protein 5 as an inhibitory target of cefozopran in Enterococcus faecalis 1996 ·Journal of Antimicrobial Chemotherapy ·Noboru Tsuchimori,Kenji Okonogi	2
12	Optically Active Antifungal Azoles. VI. Synthesis and Antifungal Activity of N-((1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-N'-(4-substituted phenyl)-3(2H,4H)-1,2,4-triazolones and 5(1H,4H)-tetrazolones. 1996 ·Chemical and Pharmaceutical Bulletin ·Tomoyuki Kitazaki,Norikazu Tamura,Akihiro Tasaka,Yoshihiro Matsushita,(unknown),Kenji Okonogi,Katsumi Itoh	25
13	Optically Active Antifungal Azoles. V. Synthesis and Antifungal Activity of Stereoisomers of 3-Azolyl-2-(substituted phenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanols. 1995 ·Chemical and Pharmaceutical Bulletin ·(unknown),Noboru Tsuchimori,Tomoyuki Kitazaki,(unknown),(unknown),Kenji Okonogi,Kazuyuki Itoh	9
14	Optically Active Antifungal Azoles. III. Synthesis and Antifungal Activity of Sulfide and Sulfonamide Derivatives of (2R,3R)-2-(2,4-Difluorophenyl)-3-mercapto-1- (lH-1,2,4-triazol-1-yl)-2-butanol. 1994 ·Chemical and Pharmaceutical Bulletin ·Akihiro Tasaka,Katsunori Teranishi,Yoshihiro Matsushita,Norikazu Tamura,(unknown),Kenji Okonogi,Katsumi Itoh	15
15	Ferrocins, new iron-containing peptide antibiotics produced by bacteria. Taxonomy, fermentation and biological activity. 1993 ·The Journal of Antibiotics ·NOZOMI KATAYAMA,YUKIMASA NOZAKI,Kenji Okonogi,SETSUO HARADA,Hideo Onο	11
16	Optically Active Antifungal Azoles. II. Synthesis and Antifungal Activity of Polysulfide Derivatives of (2R,3R)-2-(2,4-Difluorophenyl)-3-mercapto-1-(1H-1,2,4-triazol-1-yl)-2-butanol. 1993 ·Chemical and Pharmaceutical Bulletin ·Akihiro Tasaka,Norikazu Tamura,Yoshihiro Matsushita,(unknown),Kenji Okonogi,(unknown)	22
17	Optically Active Antifungal Azoles. I. Synthesis and Antifungal Activity of (2R,3R)-2-(2,4-Difluorophenyl)-3-mercapto-1-(1H-1,2,4-triazol-1-yl)-2-butanol and Its Stereoisomers. 1993 ·Chemical and Pharmaceutical Bulletin ·Akihiro Tasaka,Norikazu Tamura,Yoshihiro Matsushita,Katsunori Teranishi,(unknown),Kenji Okonogi,Katsumi Itoh	36
18	Molecular cloning and nucleotide sequence determination of the regulator region of mecA gene in methicillin‐resistant Staphylococcus aureus (MRSA) 1992 ·FEBS Letters ·Keiichi Hiramatsu,Kazumi Asada,Eiko Suzuki,Kenji Okonogi,Takeshi Yokota	150
19	A Case of Penicillin-Resistant Pneumococcal Pneumonia and Penicillin-Binding Proteins of the Clinical Isolates 1992 ·Kansenshogaku zasshi ·(unknown),Toru Yamasaki,Hiroyuki Nagai,(unknown),Takayoshi Tashiro,Masaru Nasu,(unknown),Kenji Okonogi	6
20	Emergence of methicillin-resistant clones from cephamycin-resistant Staphylococcus aureus 1989 ·Journal of Antimicrobial Chemotherapy ·Kenji Okonogi,(unknown),Masahiro Kondo,Akira Imada,Takeshi Yokota	37

About Kenji Okonogi

Kenji Okonogi is a scholar working on Molecular Medicine, Pharmacology and Infectious Diseases, having authored 54 papers that have together received 1.9k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (18 papers), Antibiotics Pharmacokinetics and Efficacy (16 papers) and Antimicrobial Resistance in Staphylococcus (14 papers). The work is most often cited by research in Virology (465 citations), Molecular Medicine (235 citations) and Infectious Diseases (685 citations). Kenji Okonogi has collaborated with scholars based in Japan, United States and Brazil. Frequent co-authors include Yuji Iizawa, Masanori Baba, Mika Okamoto, Naoyuki Kanzaki, Mitsuru Shiraishi, Kanji Meguro, Osamu Nishimura, Yasuaki Ogawa, Masahiko Fujino and Yoshio Aramaki. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and FEBS Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact